Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Recruiting now · Phase 2

Conditions studied: Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)

In brief

Primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL) is a highly aggressive malignancy accounting for over 80% of primary CNS lymphomas, with an annual incidence of 0.4-0.6 per 100,000 people globally and a rising trend in immunocompetent patients. First-line high-dose methotrexate-based chemotherapy causes severe toxicities and nearly 50% of patients relapse within 1-2 years, developing relapsed/refractory (R/R) disease. Treatment options for R/R PCNSL are scarce, with low response rates, median survival of only 3-6 months, and 5-year survival below 5%. The blood-brain barrier and tumor heterogeneity further worsen outcomes. This prospective, multicenter, single-arm phase II study evaluates the efficacy and safety of pomalidomide, PD-1 inhibitor, and selinexor (PPS) in R/R PCNSL, aiming to provide a new effective treatment.

Key facts

Study ID

NCT07523737

Run by

Beijing Tongren Hospital

People needed

43

Starts

2026-04-01

Expected to finish

2028-08-31

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL).
• Disease progression or relapse after prior treatment with high-dose methotrexate and/or BTK inhibitors.
• Age between 18 and 75 years.
• ECOG performance status score 0-4.
• Expected overall survival > 3 months.
• No known hypersensitivity to any study drug.
• White blood cell count ≥ 3×10⁹/L; absolute neutrophil count ≥ 1.0×10⁹/L; platelet count ≥ 50×10⁹/L.
• Serum creatinine ≤ 1.5 mg/dL; creatinine clearance ≥ 50 mL/min.
• ALT and AST ≤ 3× upper limit of normal (ULN); total bilirubin ≤ 2× ULN.
• Signed written informed consent.

You may not qualify if…

• Presence of another malignant tumor requiring active pharmacological or surgical intervention at present;
• Female patients who are pregnant or breastfeeding;
• Patients (male or female) of reproductive potential who are unwilling to use or fail to use effective contraceptive measures;
• Known hypersensitivity to any study drug or any excipient ingredients of these products;
• Active infection (determined by the investigator);
• History of immunodeficiency, including positive HIV status, other acquired or congenital immunodeficiency disorders, or history of organ transplantation;
• Documented history of neurological or psychiatric disorders, including epilepsy or dementia;
• Documented history of autoimmune diseases (except Hashimoto's thyroiditis or thyroid dysfunction);
• Any severe comorbidity that, in the investigator's judgment, would compromise patient safety or interfere with the completion of the study.

Where it is running

• Beijing Tongren Hospital, Capital Medical University — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.